Taiwan is strong in medtech and biotech. Health money comes from bio-funds, hospitals, and the state. Pure digital-health VC is still small. Here are 9 investors backing Taipei healthtech in 2026.
Taiwan builds medical devices at scale, and its biotech sector runs deep. That base shapes where health capital comes from and what investors expect to see.
Health money here is specialist rather than broad. Bio-funds and hospitals lead most rounds, and they price deals on clinical strength.
The government backs biotech through dedicated centers and funds. Pure digital-health VC stays small, so founders raise from health-native backers.
You need the right backers and clean files to move fast. Ellty keeps your data in one tracked link, so every fund sees the same current version.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Diamond Biofund | Biotech VC (listed) | Single-digit US$M+ | New drugs, medtech, devices | diamondbiofund.com |
| Taiwan Global BioFund | Biotech VC | Venture-scale | Pharma, medtech, diagnostics | TGB on LinkedIn |
| BE Health Ventures | Hospital-backed VC | US$100K-$1M+ | Medical devices, digital health | behealthventures.com |
| Taiwania Capital | Biotech VC | Series A to growth | Biotech, pharma, medtech | taiwaniacapital.com |
| CDIB Healthcare Fund | Biomed PE-VC | US$2M-$10M | Biopharma, medtech, digital health | cdibcapitalgroup.com |
| Vivo Capital | Cross-border health VC | Single to tens of US$M | Biopharma, medtech, diagnostics | vivocapital.com |
| DCB | Government bio-fund | Early-stage | Biologics, drugs, medtech | dcb.org.tw |
| H. Spectrum | Health accelerator | Accelerator-scale | Digital health, biosensors | ylhspectrum.com |
| Maxpro Ventures | Biomedical VC | US$1M-$5M | Biomedical, life sciences | maxproventures.com |
Keep your health data room ready before the call
Health investors study your trials, data, and approval path. Ellty logs every view so you know who is serious.
Start free 14-day trialWhat a healthtech investor backs
They back real clinical proof, not ideas alone. Trials and data carry the weight, and a thin story rarely clears the first meeting.
Regulation shapes every health deal here. Investors expect a clear path to market, with the approvals and milestones already mapped.
Patient data must stay protected at each step. A clean fundraising file helps you show that you handle sensitive records with care.
Ellty gives each fund one tracked link. You see who reads your trial data, so you know which conversations are worth your time.
Taiwan's biotech sector showed resilience in 2024, with 15 companies going public and raising about US$68 million, and five more IPOs in the first half of 2025.
9 Taipei healthtech investors
1. Diamond Biofund
Diamond is the first VC listed on Taiwan's main board.
Recent Activity: First VC listed on the Taiwan main board
LinkedIn: Diamond Biofund LinkedIn
Sector Focus: New drugs, medtech, devices
Stage Focus: Seed to growth
Check Size: Single-digit US$M+
Location: Taipei
Website: diamondbiofund.com
2. Taiwan Global BioFund
TGB is Taiwan's longest-running biotech fund.
Recent Activity: Long-running biotech VC, advised by YFY Biotech
LinkedIn: Taiwan Global BioFund LinkedIn
Sector Focus: Pharma, medtech, diagnostics
Stage Focus: Seed to late venture
Check Size: Venture-scale
Location: Taipei
Website: TGB on LinkedIn
3. BE Health Ventures
BE is Taiwan's only hospital-backed VC.
Recent Activity: Backed 33+ medtech startups since 2018
LinkedIn: BE Health Ventures LinkedIn
Sector Focus: Medical devices, digital health
Stage Focus: Early stage, seed
Check Size: US$100K-$1M+
Location: Taipei
Website: behealthventures.com
4. Taiwania Capital
Taiwania runs a dedicated life science fund.
Recent Activity: Launched a US$200M life science fund in 2024
LinkedIn: Taiwania Capital LinkedIn
Sector Focus: Biotech, pharma, medtech
Stage Focus: Series A to growth
Check Size: Series A to growth
Location: Taipei
Website: taiwaniacapital.com
5. CDIB Healthcare Fund
CDIB runs a dedicated biomedical fund.
Recent Activity: Raised a ~US$97M healthcare fund
Sector Focus: Biopharma, medtech, digital health
Stage Focus: Growth, later venture
Check Size: US$2M-$10M
Location: Taipei
Website: cdibcapitalgroup.com
6. Vivo Capital
Vivo is a US-Asia healthcare fund in Taipei.
Recent Activity: Launched Taiwan's first biotech PE fund in 2025
Sector Focus: Biopharma, medtech, diagnostics
Stage Focus: Preclinical to growth
Check Size: Single to tens of US$M
Location: Palo Alto, USA
Website: vivocapital.com
Share one link with every health investor
Ellty shows when a fund opens your trial data. Follow up at the right moment, not days later.
Start free 14-day trial7. DCB
DCB is Taiwan's government biotech center.
Recent Activity: Government bio center backing translation
LinkedIn: DCB LinkedIn
Sector Focus: Biologics, drugs, medtech
Stage Focus: Seed, early stage
Check Size: Early-stage
Location: New Taipei
Website: dcb.org.tw
8. H. Spectrum
H. Spectrum is a leading APAC health accelerator.
Recent Activity: Runs programs with the Merck Innovation Lab
LinkedIn: H. Spectrum LinkedIn
Sector Focus: Digital health, biosensors, medtech
Stage Focus: Pre-seed, seed
Check Size: Accelerator-scale
Location: Taipei
Website: ylhspectrum.com
9. Maxpro Ventures
Maxpro is a founder-led biomedical fund.
Recent Activity: An early backer of PharmaEssentia
Sector Focus: Biomedical, life sciences
Stage Focus: Series A
Check Size: US$1M-$5M
Location: Taipei
Website: maxproventures.com
Why health money is specialist
Health deals need deep expertise to judge well. Generalist VCs mostly stay out, since they cannot read a trial or weigh an approval risk.
Bio-funds and hospitals lead instead. They know trials and approvals first-hand, and they back teams who can navigate both.
The state backs early biotech as well, filling gaps that private money skips. See our AI investors guide too for the wider Taipei picture.
Ellty lets you share trial data safely with each fund. Track every open in one place, so you know who is genuinely reviewing your work.
Navigating health regulation
Health rules are strict and slow to clear. Plan for trials and approvals early, and build the timeline into your raise.
Patient data needs tight control at every handoff. Use secure file sharing for it so sensitive records never travel unprotected.
Lock records behind a login when the data is sensitive. Add password protection to each room so only invited reviewers get in.
Ellty stores every file in one place. You decide who sees each record, and you can revoke access the moment a conversation ends.
Raising for a long health timeline
Health startups take years to reach an exit. Plan a long, funded runway, because trials and approvals rarely move quickly.
Keep backers close through every trial milestone. Use investor relations tools for it so your supporters stay informed and engaged.
Send clear updates at each stage of progress. Try investor update software for it to keep your reporting consistent and on time.
Ellty shows who reads your data room. Share it as one virtual data room link, so the whole raise runs from a single source.
How to pitch a healthtech investor
Lead with clinical proof.
- 1.Lead with clinical proof.Show real trial data up front, not just a vision for the product. Health investors trust evidence, so let your results carry the opening.
- 2.Map your path to approval.Show you know the rules and the milestones that stand between you and the market. A clear regulatory plan tells investors you can execute, not just invent.
- 3.Name your raise and long runway.Health takes time, so state how much you need and how far it carries you. Tie each milestone to the capital that funds it.
- 4.Send one Ellty link to your data.Share a single tracked link to your deck and trial files. Watch who digs in, and follow up with the funds that linger on the detail.
How Ellty helps you land a healthtech investor in Taipei
You have your Taipei healthtech list ready. Set up a data room before the first call.
- 1.Upload your deck, trial data, and metrics.Set access per fund.
- 2.Share one trackable link per fund.Each fund gets a unique link.
- 3.Watch opens and reply on time.Use analytics to time each nudge.
Taipei healthtech investor questions
- Bio-funds, hospitals, and the state. A few cross-border funds too.
- No, it is still small. Biotech and devices lead.
- Often US$1M to tens of millions. Biotech rounds run large.
- Yes, through DCB and bio-funds. It funds early research.
- Clinical proof and a clear path. Trials matter most.
- Before your first investor call. Track who opens your data.
